Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Clinical Trials
750
Trial Phases
5 Phases
Drug Approvals
5
Clinical Trials
Distribution across different clinical trial phases (667 trials with phase data)• Click on a phase to view related trials
First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)
- Conditions
- Parkinsons Disease
- Interventions
- Drug: ALN-SNCADrug: Placebo
- First Posted Date
- 2025-10-14
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 46
- Registration Number
- NCT07216066
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
- Conditions
- Symptomatic Venous Thromboembolism (VTE)
- Interventions
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 2000
- Registration Number
- NCT07213778
A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)Persistent Anemia
- Interventions
- Drug: ALN-CFBDrug: Placebo
- First Posted Date
- 2025-09-23
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT07187401
Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 85
- Registration Number
- NCT07187089
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 1200
- Registration Number
- NCT07175428
- Prev
- 1
- 2
- 3
- 4
- 5
- 72
- Next
News
Excellergy Raises $70M Series A to Advance Novel Trifunctional Allergy Treatment Platform
Excellergy secured $70 million in Series A funding to develop first-in-class trifunctional Effector Cell Response Inhibitors (ECRIs) for allergic conditions.
Regeneron's DB-OTO Gene Therapy Restores Hearing in 11 of 12 Children with Genetic Hearing Loss
Regeneron's investigational gene therapy DB-OTO demonstrated clinically meaningful hearing improvements in 11 of 12 children with profound genetic hearing loss due to OTOF gene variants in the pivotal CHORD trial.
Eli Lilly and AstraZeneca Emerge as Leading Candidates for Next Trump Administration Drug Pricing Deal
Wall Street analysts predict Eli Lilly and AstraZeneca are the most likely pharmaceutical companies to strike the next drug pricing deal with the Trump administration following Pfizer's September 29 agreement.
Amgen's Repatha Demonstrates Long-Term Cardiovascular Benefits in Phase III VESALIUS-CV Trial
Amgen's Phase III VESALIUS-CV trial met both primary endpoints, demonstrating that Repatha significantly reduces major adverse cardiovascular events in high-risk patients without prior heart attack or stroke.
MiNK Therapeutics Appoints Dr. Terese Hammond to Lead iNKT Cell Therapy Pipeline Toward Pivotal Trials
MiNK Therapeutics has appointed Dr. Terese C. Hammond as Head of Inflammatory and Pulmonary Diseases to accelerate their invariant natural killer T (iNKT) cell therapy pipeline toward pivotal development.
Regeneron's Garetosmab Achieves 90% Reduction in Bone Formation in Rare Disease Trial
Regeneron's Phase 3 OPTIMA trial of garetosmab met its primary endpoint, demonstrating a 90% or greater reduction in new heterotopic ossification lesions in adults with fibrodysplasia ossificans progressiva at 56 weeks.
Ollin Biosciences Emerges with $100M to Challenge Leading Eye Disease Treatments
Ollin Biosciences launched with $100 million in Series A funding led by ARCH Venture Partners, Mubadala Capital, and Monograph Capital to develop next-generation ophthalmology treatments.
Dualitas Therapeutics Emerges from Stealth with $65M Series A to Advance Bispecific Antibody Pipeline
Dualitas Therapeutics launched from stealth with $65 million Series A funding co-led by Versant Ventures and Qiming Venture Partners USA, with participation from Eli Lilly and Company and other strategic investors.
Australian Court Denies Preliminary Injunction Against Sandoz Aflibercept Biosimilar Launch
The Federal Court of Australia denied Regeneron and Bayer's preliminary injunction application against Sandoz's aflibercept biosimilars, allowing the launch of Afqlir and Enzeevu to proceed as planned.
Regeneron's Libtayo Combination Therapy Demonstrates 19.4% Five-Year Survival Rate in Advanced Lung Cancer
Regeneron's Phase 3 EMPOWER-Lung 3 trial shows Libtayo plus chemotherapy achieved a 19.4% five-year survival rate compared to 8.8% with chemotherapy alone in advanced non-small cell lung cancer patients.